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Abstract 
Background: This study aimed to evaluate the effect of adenosine on epicardial coronary artery diam-
eter during ergonovine provocation testing. 
Methods: A total of 158 patients who underwent an ergonovine provocation test with intracoronary 
adenosine injection between 2011 and 2014 were selected. Patients were divided into four groups based 
on the severity of percent diameter stenosis following intracoronary ergonovine administration: Group 1,  
induced spasm < 50%; Group 2, 50–89%; Group 3, 90–99%; and Group 4, total occlusion.
Results: Spasm positivity was observed in 44 (27.8%) cases in the study population (mean age, 57.4 ±  
± 10.7 years). Intracoronary adenosine increased the diameter of the ergonovine-induced epicardial 
artery by 0.51 ± 0.31 mm, 0.73 ± 0.39 mm, 0.44 ± 0.59 mm, and 0.01 ± 0.04 mm in Groups 1, 2, 3,  
and 4, respectively. Subsequent administration of nitroglycerin further increased vessel diameter by 
0.49 ± 0.28 mm, 0.93 ± 0.68 mm, 2.11 ± 1.25 mm, and 2.23 ± 0.69 mm in Groups 1, 2, 3, and 4, 
respectively. The ratios of adenosine-induced diameter to reference diameter were significantly lower 
in patients with spasm positive results (0.68 [0.59–0.76] vs. 0.18 [0.00–0.41], p < 0.001 in the study 
population; 0.60 [0.54–0.67] vs. 0.40 [0.27–0.44], p < 0.001 in Group 2) with the best cut-off value of 
0.505 (sensitivity 0.955, specificity 0.921). 
Conclusions: Intracoronary administration of adenosine dilated the ergonovine-induced vasocon-
stricted epicardial coronary artery. The ratio of adenosine-induced diameter to reference diameter was 
significantly lower in patients with spasm positive results. (Cardiol J 2019; 26, 6: 653–660)
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Introduction
Coronary artery spasm has been recognized 
as the main pathomechanism for variant angina, 
as well as acute myocardial infarction and sudden 
cardiac death in severe cases [1–4]. It has been 
shown to be correlated with early atherosclerosis 
and has a higher prevalence in Asian populations 
than Caucasians [5, 6]. Ergonovine maleate is 
a weak vasoconstrictor, and induces a vasoconstric-
tor response in susceptible epicardial coronary 
arteries. This response is mediated by endotheli-
um-independent smooth muscle hyperconstriction 
and more pronounced with endothelial dysfunction 
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[7, 8]. In patients with confirmed variant angina, 
ergonovine provocation can induce coronary artery 
spasm at the same site where spontaneous spasm 
was observed with high diagnostic sensitivity and 
specificity [9, 10]. Adenosine is an endogenous 
neurotransmitter that can be synthesized by de 
novo purine biosynthesis or produced by degrada-
tion of 5’-adenosine triphosphate and 5’-adenosine 
monophosphate [11, 12]. Its biologic effects include 
inhibition of platelet aggregation, modulation of 
the inflammatory response, negative chronotropic 
and dromotropic effects, and induction of coronary 
vasodilation, predominantly affecting microves-
sels < 150 μm in diameter [13]. Due to its potent 
vasodilator effect in coronary microvessels, it has 
been the most widely used drug to achieve hy-
peremia while measuring fractional flow reserve 
(FFR) in the coronary artery bed. However, the 
effect of adenosine on the ergonovine-induced 
vasoconstricted epicardial coronary artery has 
not been elucidated. The purpose of this study 
was to investigate the response of ergonovine-
induced vasoconstricted epicardial coronary artery 
to adenosine and to clarify the suitability of FFR 
measurement using intracoronary adenosine on 
that vasocontricted epicardial coronary artery.
Methods
Study population
From June 2011 to June 2014, the spasm provo-
cation test with selective intracoronary injection of 
ergonovine was performed in 464 patients deemed 
to have variant angina. When a spasm was induced, 
adenosine administration into the spasm-induced 
coronary artery has been recommended routinely 
since 2011. A total of 158 patients who received 
intracoronary adenosine during the provocation 
test were identified and analyzed retrospectively. 
Informed consent for the test using both ergono-
vine and adenosine was obtained from each patient, 
and the study was approved by the Institutional 
Review Board of the hospital.
Ergonovine provocation test
The left coronary artery (LCA) and the right 
coronary artery (RCA) were provoked to spasm ac-
cording to a standard manner recommended by the 
Japanese Circulation Society [14, 15]. Calcium an-
tagonists, long-acting nitrates, and nicorandil were 
discontinued at least 48 h before the provocation 
test, except for as needed sublingual nitroglycerin. 
Baseline coronary angiography was obtained 
with a 5-French (Fr) catheter via the femoral or 
radial artery (57 cases), which have been the 
default access points since 2012. The provocation 
test was performed when there was no significant 
stenosis (> 75% luminal narrowing). Stepwise 
doses of methylerogometrine maleate (ER) (Dae-
won Pharm, Seoul, Korea) were selectively admin-
istered into the LCA (10, 20, and 20 μg) and RCA 
(10, 10, and 20 μg) with 3-min intervals between 
each dose. RCA spasm provocation was initiated 
after a 5-min washout period following LCA provo-
cation. Coronary angiograms were obtained with 
each ER administration or when chest pain and/or 
ST-segment changes occurred. A selective dose 
of adenosine, 60 μg for the LCA and 40 μg for the 
RCA corresponding to the standard dose for FFR 
measurement, was injected into the coronary ar-
tery which had the maximum induced spasm and 
was followed by repeated coronary angiogram [16]. 
Intracoronary nitroglycerin was then administered 
until the spasm was entirely relieved and final 
coronary angiogram was performed.
A positive response was defined as transient 
greater than 90% diameter stenosis on coronary 
angiography, regardless of symptoms or sign of 
ischemia, or greater than 70% diameter stenosis 
with ischemic electrocardiography (ECG) changes 
and/or chest pain.
Quantitative angiographic analysis
End-diastolic cineframes in the same projec-
tion were selected and analyzed separately by two 
independent investigators using QCA software 
(Xcelera, Philips Medical Systems, the Nether-
lands). The coronary artery luminal diameter was 
measured in millimeters using a contrast-filled 
catheter as the calibration source. The most se-
verely narrowed segment was termed the spasm 
segment and its diameter in response to ER, adeno-
sine, and nitroglycerin were termed DiameterER, 
DiameterAde, and DiameterNit, respectively. When 
control angiograms of the LCA were obtained after 
a full-dose provocation of the RCA, the diameter 
was noted as DiameterControl. Reference diameter 
(DiameterRef) was defined as the average of the 
diameter of the nearest normal-looking segments 
before and after the spasm segment. The degree of 
induced spasm was calculated as [1 – (DiameterER / 
/DiameterRef)] × 100 and noted as %Spasm. The 
differences in diameter between DiameterER and 
DiameterAde, and between DiameterNit and DiameterAde 
were noted as ∆Adenosine and ∆Nitroglycerin, 
respectively. The sum of the change in diameter 
between DiameterER and DiameterNit was calculated 
as ∆Sum = DiameterNit – DiameterER. 
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Statistical analysis
For the purpose of this study, patients were 
categorized into four groups according to the 
%Spasm as follows: Group 1, 0–50%; Group 2, 
50–90%; Group 3, 90–99%; Group 4, total occlu-
sion. The normality of continuous data was tested 
using the Kolmogorov-Smirnov test. Skewed 
variables were analyzed after logarithmic or power 
transformation, accordingly. Continuous variables 
are expressed as the mean ± standard deviation 
(SD) or median (interquartile range) and assessed 
with the Student t-test or Mann-Whitney U test. 
Within-group comparisons were performed with 
repeated measures analysis of variance (ANOVA) 
with post hoc analysis using Bonferroni correc-
tions. Comparison of the mean values among 
groups was made using one-way ANOVA. Trends 
were assessed using the linear-by-linear asso-
ciation c2 test or the linear term in ANOVA. Cat-
egorical variables are presented as frequencies and 
compared using the Fisher exact probability test. 
The receiver-operating curve was created to draw 
the best cut-off value of the ratio of DiameterAde / 
/DiameterRef and discriminate the result of the 
spasm test. Correlations between variables were 
tested using linear regression analysis. Multivari-
ate linear regression analysis was applied to iden-
tify the predictors for the DiameterAde / DiameterRef 
ratio. Statistical significance was defined as p < 
< 0.05. All statistical calculations were performed 
using the SPSS software version 17.0 (IBM SPSS 
Inc., Chicago, IL).
Results
Clinical characteristics
A total of 158 patients were included in the 
study and categorized into the following four 
groups: Group 1, 50 (32.9%) patients; Group 2, 82 
(51.9%) patients; Group 3, 9 (5.7%) patients; and 
Group 4, 15 (9.5%) patients. The mean age was 
57.4 ± 10.7 years without significant differences 
among groups (Table 1). There was a tendency for 
increasing male population (p < 0.001) and current 
smoking (p = 0.037) from Groups 1–4. No significant 
difference was seen in the incidence of diabetes 
mellitus, hypertension, hyperlipidemia and clinical 
presentations between groups.
Methylerogometrine maleate provocation test 
was performed via the radial artery in 57 (36.1%) 
and femoral artery in 101 (63.9%) patients (Table 2). 
Overall, 44 (27.8%) patients had a positive re-
sponse. There were no provocation-related adverse 
events including death, myocardial infarction, 
stroke, or bleeding that required a procedure or 
transfusion. There was 1 case of contrast allergy, 
and 3 cases of self-limiting and transient bradycar-
dia in response to adenosine. 
Changes in vessel diameter
The investigated vessels were the left ante-
rior descending artery (LAD) and its branches in 
60 (38.0%) patients, left circumflex artery (LCX) 
and its branches in 12 (7.6%), RCA and its branches 
in 82 (51.9%), and left main in 4 (2.5%) patients. 
Two representative cases are depicted in Figure 1. 
The cumulative dose of injected ER was sig-
nificantly lower in Groups 3 and 4, compared with 
the other groups. Although DiameterRef was simi-
lar between groups, DiameterER, DiameterAde, 
and DiameterNit progressively decreased from 
Group 1 to Group 4. 
Adenosine was administered into the same 
coronary artery immediately after the angiogram of 
the last dose of ER in 114 cases (32 LCA, 82 RCA). 
In the remaining 44 cases, adenosine was injected 
into the LCA after a full provocation of the RCA, 
where control angiograms of the LCA revealed an 
increase in diameter of the vessel (DiameterER, 
1.65 ± 0.75 mm; DiameterControl, 1.90 ± 0.75 mm). 
Adenosine further dilated the vessel (DiameterAde, 
2.31 ± 0.76 mm), but lesser than DiameterNit 
(2.82 ± 0.82 mm) in those patients. Overall, the 
increase in diameter with adenosine (∆Adenosine) 
progressively decreased from Group 1 to Group 4, 
but the amount by nitroglycerin (∆Nitroglycerin) 
did vice versa. Adenosine did not increase the ves-
sel diameter in Group 4 (DiameterER, 0.00 ± 0.00; 
DiameterAde, 0.01 ± 0.04, paired t-test p = 0.334). 
Adenosine response based on test results
All patients in Group 3 and 4 had spasm posi-
tive results using the angiographic definition, while 
20 (24.5%) had spasm positive results in Group 
2. There was a significant increase in diameter 
following adenosine and nitroglycerine injection 
regardless of the result of the spasm test. Overall, 
there was a significant interaction between the 
pattern of diameter increase and the test result 
(n = 158; F [1.597, 249.1] = 77.271; p < 0.001) 
(Fig. 2A). There was a greater increase in diameter 
following adenosine injection (∆Adenosine) in 
those with spasm negative results, than in those 
with spasm positive results (0.64 ± 0.36 vs. 0.41 ± 
± 0.50, p = 0.002). The increase in diameter follow-
ing nitroglycerine (∆Nitroglycerin) was significant-
ly greater in those with spasm positive results than 
those with spasm negative results (1.84 ± 0.98 vs. 
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Table 2. Angiographic characteristics.
Group 1  
(n = 50)
Group 2  
(n = 82)
Group 3  
(n = 9)
Group 4  
(n = 15)
Total  
(n = 158)
P 
Spasm positive 0 (0.0%) 20 (24.4%) 9 (100%) 15 (100%) 44 (27.8%) < 0.001
Radial approach 15 (28.8%) 27 (32.9%) 6 (66.7%) 9 (60.0%) 57 (36.1%) 0.031*
Investigated vessel
LAD and subbranches 15 (28.8%) 35 (42.7%) 1 (11.1%) 9 (60.0%) 60 (38.0%) 0.038
LCX and subbranches 3 (5.8%) 5 (6.1%) 2 (22.2%) 2 (13.3%) 12 (7.6%) 0.185
RCA and subbranches 31 (59.6%) 41 (50.0%) 6 (66.7%) 4 (26.7%) 82 (51.9%) 0.121
Left main 3 (5.8%) 1 (1.2%) 0 (0.05) 0 (0.0%) 4 (2.5%) 0.536
Cumulative dose  
of ergonovine [μg]
90 (90–90) 90 (90–90) 60 (40–90) 30 (10–55) 90 (90–90) < 0.001
DiameterRef [mm] 3.46 ± 0.74 3.49 ± 0.78 3.49 ± 0.89 3.14 ± 0.79 3.45 ± 0.77 0.455
DiameterER [mm] 2.14 ± 0.56 1.12 ± 0.42 0.29 ± 0.09 0.00 ± 0.00 1.30 ± 0.82 < 0.001*
DiameterAde [mm] 2.66 ± 0.66 1.85 ± 0.57 0.73 ± 0.61 0.01 ± 0.04 1.88 ± 0.97 < 0.001*
DiameterNit [mm] 3.14 ± 0.76 2.77 ± 0.77 2.84 ± 0.99 2.25 ± 0.67 2.86 ± 0.81 0.001*
DiameterAde/DiameterRef 0.76 ± 0.09 0.54 ± 0.15 0.22 ± 0.20 0.01 ± 0.02 0.55 ± 0.26 < 0.001*
∆Adenosine [mm] 0.51 ± 0.31 0.73 ± 0.39 0.44 ± 0.59 0.01 ± 0.04 0.58 ± 0.42 < 0.001*
∆Nitroglycerin [mm] 0.49 ± 0.28 0.93 ± 0.68 2.11 ± 1.25 2.23 ± 0.69 0.97 ± 0.83 < 0.001*
∆Sum [mm] 1.00 ± 0.42 1.66 ± 0.70 2.55 ± 0.96 2.25 ± 0.67 1.54 ± 0.78 < 0.001*
Values are mean ± standard deviation or median (interquartile range) or number (percentage).*P value for trend was < 0.05. LAD — left anterior 
descending artery; LCX — left circumflex artery; RCA — right coronary artery
Table 1. Demographic and laboratory characteristics.
Group 1  
(n = 50)
Group 2  
(n = 82)
Group 3  
(n = 9)
Group 4  
(n = 15)
Total  
(n = 158)
P
Age [years] 56.7 ± 11.7 58.1 ± 10.9 60.0 ± 7.0 54.7 ± 7.6 57.4 ± 10.7 0.569
Male 23 (44.2%) 52 (63.4%) 7 (77.8%) 14 (93.3%) 96 (60.8%) 0.002
BMI [kg/m2] 23.6 (21.5–25.5) 24.5 (23.1–26.5) 25.1 (23.1–28.8) 23.4 (22.4–26.0) 24.1 (22.5–26.3) 0.232
Hypertension 17 (32.7%) 31 (37.8%) 7 (77.8%) 5 (33.3%) 60 (38.0%) 0.090
Diabetes mellitus 5 (9.6%) 12 (14.6%) 2 (22.2%) 4 (26.7%) 23 (14.6%) 0.265
Hyperlipidemia 35 (67.3%) 46 (56.1%) 5 (55.6%) 8 (53.3%) 94 (59.5%) 0.551
Current smoking 9 (17.3%) 28 (34.1%) 6 (66.7%) 5 (33.3%) 48 (30.4%) 0.014*
Chest pain 41 (78.8%) 62 (75.6%) 9 (100.0%) 13 (86.7%) 125 (79.1%) 0.393
CCS grade 3 and 4 25 (48.1%) 41 (50.0%) 4 (44.4%) 10 (66.7%) 80 (50.6%) 0.619
Syncope 4 (7.7%) 11 (13.4%) 0 (0.0%) 0 (0.0%) 15 (9.5%) 0.370
Post CPR 1 (1.9%) 1 (1.2%) 1 (11.1%) 1 (6.7%) 4 (2.5%) 0.142
SBP [mmHg] 127.7 ± 21.0 124.4 ± 17.1 125.3 ± 27.7 122.5 ± 16.3 125.3 ± 19.0 0.718
HR [bpm] 71.7 ± 16.0 73.7 ± 13.2 69.3 ± 16.1 69.5 ± 10.4 72.4 ± 14.1 0.595
TC [mg/dL] 197.3 ± 33.5 181.1 ± 39.0 168.9 ± 30.0 190.7 ± 69.3 186.6 ± 41.2 0.080
Cr [mg/dL] 0.71 (0.65–0.88) 0.82 (0.68–0.97) 0.88 (0.72–1.05) 0.80 (0.67–0.89) 0.80 (0.66–0.94) 0.229
Hb [g/dL] 12.8 ± 2.5 13.7 ± 1.6 15.0 ± 1.6 14.6 ± 1.3 13.6 ± 2.0 0.001
hsCRP [mg/dL] 0.06 (0.03–0.17) 0.08 (0.02–0.25) 0.14 (0.03–0.22) 0.09 (0.03–0.37) 0.08 (0.03–0.22) 0.836
Values are mean ± standard deviation or median (interquartile range) or number (percentage). *P value for trend was < 0.05. BMI — body 
mass index; CCS — Canadian Cardiovascular Society; CPR — cardiopulmonary resuscitation; SBP — systolic blood pressure; HR — heart 
rate; TC — total cholesterol; Cr — creatinine; Hb — hemoglobin; hsCRP — high sensitivity C-reactive protein
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0.64 ± 0.44, p < 0.001). There was also a significant 
interaction between diameter changes and the test 
results in Group 2 (F [1.567, 125.323] = 11.877, 
p < 0.001) (Fig. 2B). The ∆Adenosine of those 
with spasm negative results and with spasm posi-
tive results were similar (0.75 ± 0.37 vs. 0.70 ± 
± 0.46, p = 0.648). However, the ∆Nitroglycerin 
was significantly greater in those with spasm 
positive results than in those with spasm negative 
results (0.77 ± 0.51 vs. 1.41 ± 0.89, p < 0.001).
Figure 1. Coronary angiogram of representative cases. A. The sequential coronary angiogram of the right coronary 
artery (RCA) of an 82-year-old male. Intracoronary injection of ergonovine provokes spasm in the distal part of the RCA 
with a diameter of 0.60 mm (85% stenosis, arrow). Intracoronary administration of adenosine dilates it to a diameter 
of 0.88 mm. A full vasodilation is achieved by nitroglycerine injection and the calculated reference vessel diameter is 
3.92 mm resulting in the ratio of Diameterade to Diameterref of 0.23; B. The sequential coronary angiogram of the RCA of 
a 59-year-old female. The induced spasm is noted in the middle segment of the RCA (91% stenosis, arrow). Intracoro-
nary administration of adenosine dilated it to a diameter of 1.84 mm with the ratio of DiameterAde to DiameterRef of 0.67.
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Figure 2. Mean diameter changes after ergonovine, adenosine, and nitroglycerin administration. A. Mean diameter 
changes in response to a maximum dose of ergonovine (Emax), adenosine (A), and nitroglycerin (N) according to the 
result of a spasm test in the overall study population; B. Mean diameter changes in response to the agents, respec-
tively, in Group 2 (induced spasm between 50% and 90%); p values for interaction between the groups with negative 
and positive results.
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Ratio of DiameterAde to DiameterRef
Compared with the reference vessel diameter 
or the ratio of DiameterAde to DiameterRef, vessel 
diameter after adenosine injection was significantly 
smaller in patients with spasm positive results 
than in those with negative results in the overall 
study population (median, 0.18 vs. 0.68, p < 0.001) 
(Fig. 3A). A similar trend was seen for the ratio in 
Group 2 (median, 0.40 vs. 0.60, p < 0.001) (Fig. 3B). 
The best cut-off value for the prediction of a spasm 
positive result was 0.505, with a sensitivity of 96% 
and specificity of 92% (Fig. 4). Multivariate linear 
regression analysis found that current smoking 
(odds ratio [OR] 0.219; confidence interval [CI] 
0.047–0.390) and drinking alcohol (OR 0.095; CI 
0.033–0.157) were significantly associated with 
a DiameterAde to DiameterRef ratio less than 0.505, 
after adjusting for age, sex, investigated vessel, 
HbA1c, and high sensitivity C-reactive protein. 
According to available research, this is the 
first study investigating the effect of adenosine 
on ER-induced constricted coronary arteries in 
humans. It was demonstrated that: 1) intracoronary 
administration of adenosine dilated the ER-induced 
constricted coronary artery; 2) this effect was not 
observed in the completely occluded coronary 
artery in response to ER; 3) the vessel diameter 
after adenosine administration and its ratio to 
the reference vessel diameter were significantly 
smaller in patients with spasm positive results than 
in those with spasm negative results; and 4) the 
ratio cut-off value of 0.505 had a high sensitivity 
(96%) and high specificity (92%) in the prediction 
of a spasm positive result.
Discussion
Coronary blood flow is regulated via changes 
in vessel diameter, and vascular resistance of the 
coronary arteries adjusts to meet the demands for 
myocardial oxygen [13, 17]. This intrinsic ability 
Figure 4. Receiver operating characteristics curve for 
DiameterAde/DiameterRef for the result of spasm positive. 
A ratio of vessel diameter in response to adenosine 
injection (DiameterAde) to the diameter of the reference 
vessel (DiameterRef) of 0.505 best predicts a positive 
spasm result with a sensitivity of 96% and specificity 
of 92%; AUC — area under curve; CI — confidence 
interval.
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Figure 3. Box plot for the ratio of DiameterAde to DiameterRef. A. Ratio of vessel diameter in response to adenosine 
injection (DiameterAde) to diameter of the reference vessel (DiameterRef) according to the test result in the overall study 
population; B. Ratio of DiameterAde to DiameterRef in Group 2 (induced spasm between 50% and 90%). Values are 
presented with median (interquartile range); p values are derived by Mann-Whitney U test.
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of the heart is called autoregulation. It occurs over 
a wide range of coronary perfusion pressures, 
primarily mediated by metabolic, myogenic, and en-
dothelial mechanisms [18]. Autoregulatory dilation 
occurs substantially in small coronary arterioles 
with diameters less than 150 μm, which are the ma-
jor site of action of adenosine. Adenosine is a purine 
nucleoside produced naturally in myocardial cells 
from the breakdown of adenosine triphosphate dur-
ing myocardial ischemia [13]. This dilation of small 
coronary arterioles reduces vascular resistance 
and decreases the pressure of upstream vessels, 
followed by vasodilation of larger arterioles and 
small arteries (140–300 μm diameter), resulting 
in an increase in coronary blood flow [17, 19]. The 
question is how the large epicardial coronary artery 
reacts toan increased blood flow. Shiode et al. [20] 
demonstrated that adenosine infusion (100 μg/min) 
via a 3-Fr infusion catheter settled in the middle 
segment of LAD increased coronary blood flow by 
+399% in 12 patients with angiographically normal 
coronary arteries. The proximal segment of LAD, 
where there was no direct contact with infused 
adenosine, had a larger diameter by 9.2% in re-
sponse to blood flow augmentation [20]. This phe-
nomenon is explained by flow-dependent coronary 
dilation. Lupi et al. [21] further validated epicardial 
coronary artery vasodilation with intracoronary 
adenosine infusion in 24 patients with angiographi-
cally normal coronary arteries. The increase in 
coronary diameter strongly correlated with peak 
coronary blood flow velocity in response to adeno-
sine infusion, suggesting that the phenomenon was 
caused by a flow-mediated mechanism rather than 
a direct effect of adenosine [21]. A similar result 
was obtained with dipyridamole, which dilates 
epicardial coronary arteries indirectly by inhibiting 
intramyocardial adenosine re-uptake, provided sup-
portive evidence of a flow-mediated mechanism. 
Drexler et al. [22] observed flow-dependent epi-
cardial coronary artery dilation using papaverine. 
However, that response was significantly reduced 
in the coronary arteries with non-flow-limiting 
atherosclerosis, suggesting that endothelial func-
tion was involved [22]. It has been recognized 
that flow stimulation induces the endothelium to 
release endogenous vasodilators including nitric 
oxide, which subsequently dilates coronary arter-
ies [23, 24]. This mechanism was supported by an 
observation that such flow-mediated dilation was 
abolished by removing the endothelium [25]. We 
found that intracoronary-administered adenosine 
dilated the epicardial coronary artery that had been 
vasoconstricted by ER. However, adenosine did not 
dilate a completely occluded epicardial coronary 
artery in cases where adenosine could not reach 
the microvessels that it acted upon to induce flow 
augmentation. This result supports the theory that 
the dilation of epicardial coronary artery is induced 
by a flow-dependent and endothelial mechanism 
rather than a direct local effect of adenosine on the 
epicardial artery. The response was hampered in 
patients with spasm positive results. Researchers 
previously reported that healthy endothelial func-
tion render the epicardial coronary artery more 
resilient to vasospasm by producing nitric oxide 
[26]. This data may explain the hampered response 
to adenosine which was observed in the patients 
studied herein. Furthermore, we may posit that 
patients with poor adenosine response, based on 
a DiameterAde to DiameterRef ratio less than 0.50, 
are be more prone to vasospasm. 
According to the Japanese Circulation Soci-
ety, a positive finding on coronary angiography is 
defined as a transient, total or sub-total occlusion 
(> 90% stenosis) of the coronary artery [15]. How-
ever, a sizable number of patients have significant 
transient occlusion (> 50% stenosis), but do not 
meet this criterion. In this study, 24.4% of patients 
in Group 2 (50–90% stenosis) had a spasm posi-
tive result with definite ischemic ECG change. In 
a clinical context, a poor response of spasm-induced 
epicardial coronary artery to intracoronary adeno-
sine would be a marker for vasospasm severity. It 
may also be an adjunctive marker to discriminate 
patients with vasospasm angina from those without 
vasospasm when ergonovine provocation shows 
intermediate response.
Limitations of the study
Several limitations are acknowledged in the 
present study. First,  coronary blood flow and intra-
coronary pressure was not measured directly. How-
ever, it was reasonable to assume that flow would 
increase and pressure decrease after adenosine 
injection, as shown in previous studies. Second, 
a small number of patients were enrolled from 
an Asian population at a single center. Therefore, 
results should be confirmed in larger studies with 
a more diverse population. Nevertheless, the pre-
sent findings add to an understanding of coronary 
dynamics in vasospasm. 
Conclusions
The present study found that intracoronary 
administration of adenosine dilated the ergonovine-
induced vasoconstricted epicardial coronary artery. 
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However, this was not the case in a completely 
occluded coronary artery with induced vasospasm, 
suggesting that dilation was endothelial-dependent 
and flow-mediated. Adenosine by itself does not 
adequately dilate the epicardial arteries. This is 
of note especially during FFR manipulation and 
measurement, where nitroglycerin should not be 
overlooked.
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